PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) Form 8-K — Jun 30, 2026

Provectus Biopharmaceuticals' Board of Directors approved the conversion of accrued but unpaid directors' fees into Series D-1 Preferred Stock to satisfy outstanding compensation obligations. The fees, totaling $542,500, have been accruing since April 2017 and will convert into 189,554 shares of Preferred Stock at a price of $2.862 per share. This action effectively clears a long-standing liability by issuing equity rather than cash, which is convertible into approximately 1,895,540 shares of Common Stock.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.